District court denies preliminary injunctions by drug companies in challenges to Maine’s 340B contract pharmacy law
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges against the state’s law protecting 340B pricing for contract pharmacy arrangements. In particular, the court held that “Plaintiffs have failed to establish that they will likely succeed on the merits of their preemption, commerce clause, takings, [and] vagueness claims.”
The AHA, 340B Health, the Maine Hospital Association and the American Society of Health-System Pharmacists filed amicus briefs Sept. 11 and Sept. 15 opposing the preliminary injunctions. The AHA has opposed similar challenges by drug companies in multiple states.
Related News Articles
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The AHA Aug. 27 said the Health Resources and Services Administration should abandon its 340B Rebate Model Pilot Program.“It is a ‘solution’ in search of a…